Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Critical appraisal of ranibizumab in the treatment of diabetic macular edema.

Stewart MW.

Clin Ophthalmol. 2013;7:1257-67. doi: 10.2147/OPTH.S36443. Epub 2013 Jun 24.

2.

Corticosteroid use for diabetic macular edema: old fad or new trend?

Stewart MW.

Curr Diab Rep. 2012 Aug;12(4):364-75. doi: 10.1007/s11892-012-0281-8. Review.

PMID:
22581206
3.
4.
5.

The clinical utility of aflibercept for diabetic macular edema.

Stewart MW.

Diabetes Metab Syndr Obes. 2015 Sep 18;8:473-82. doi: 10.2147/DMSO.S72792. eCollection 2015. Review.

6.

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.

Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF.

Br J Ophthalmol. 2013 Apr;97(4):454-9. doi: 10.1136/bjophthalmol-2012-302451. Epub 2013 Feb 5.

PMID:
23385630
7.

Bevacizumab for the management of diabetic macular edema.

Stefanini FR, Arevalo JF, Maia M.

World J Diabetes. 2013 Apr 15;4(2):19-26. doi: 10.4239/wjd.v4.i2.19.

8.

Management paradigms for diabetic macular edema.

Mitchell P, Wong TY; Diabetic Macular Edema Treatment Guideline Working Group.

Am J Ophthalmol. 2014 Mar;157(3):505-13.e1-8. doi: 10.1016/j.ajo.2013.11.012. Epub 2013 Nov 19.

PMID:
24269850
9.

Anti-VEGF therapy for diabetic macular edema.

Stewart MW.

Curr Diab Rep. 2014 Aug;14(8):510. doi: 10.1007/s11892-014-0510-4. Review.

PMID:
24919750
10.

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.

Fong AH, Lai TY.

Clin Interv Aging. 2013;8:467-83. doi: 10.2147/CIA.S36811. Epub 2013 Apr 29. Review.

11.

Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS.

Ther Adv Endocrinol Metab. 2013 Dec;4(6):151-69. doi: 10.1177/2042018813512360. Review.

12.

Vascular endothelial growth factor and diabetic macular edema.

Lally DR, Shah CP, Heier JS.

Surv Ophthalmol. 2016 Apr 1. pii: S0039-6257(15)30035-7. doi: 10.1016/j.survophthal.2016.03.010. [Epub ahead of print] Review.

PMID:
27045225
13.

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.

Parravano M, Menchini F, Virgili G.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007419. doi: 10.1002/14651858.CD007419.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD007419.

PMID:
19821414
14.

Ranibizumab and diabetic macular oedema: after laser therapy.

[No authors listed]

Prescrire Int. 2012 Mar;21(125):66.

PMID:
22428185
15.

Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.

Hussain RM, Ciulla TA.

Expert Opin Biol Ther. 2016;16(3):365-74. doi: 10.1517/14712598.2016.1131265. Epub 2016 Jan 12.

PMID:
26674182
16.

Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.

Evoy KE, Abel SR.

Ann Pharmacother. 2013 Jun;47(6):811-8. doi: 10.1345/aph.1S013. Epub 2013 May 8. Review.

PMID:
23656749
17.

Emerging drugs for diabetic macular edema.

Schwartz SG, Flynn HW Jr, Scott IU.

Expert Opin Emerg Drugs. 2014 Sep;19(3):397-405. doi: 10.1517/14728214.2014.938048. Epub 2014 Aug 21. Review.

PMID:
25141904
18.

Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.

Sonoda Y, Arimura N, Shimura M, Sakamoto T.

Retina. 2011 Feb;31(2):290-7. doi: 10.1097/IAE.0b013e3181eef070.

PMID:
21102366
19.

Use of antivascular endothelial growth factor for diabetic macular edema.

Karim R, Tang B.

Clin Ophthalmol. 2010 May 25;4:493-517.

20.

Ranibizumab: in diabetic macular oedema.

Frampton JE.

Drugs. 2012 Mar 5;72(4):509-23. doi: 10.2165/11208410-000000000-00000. Review.

PMID:
22356289
Items per page

Supplemental Content

Write to the Help Desk